Our projects

Read more about our current projects down below or browse our full publication list here

non-muscle-invasive bladder cancer

Diagnosis

Kliniske og funktionelle konsekvenser af fotodynamisk diagnostik (PDD) og intravesical installationsterapi

Blærekræft rammer årligt cirka 2000 personer i Danmark. 75 % diagnosticeres på et tidligt stadie, hvor kræften endnu ikke er vokset ned i blærens muskulatur. Dette kaldes ikke-muskelinvasivblærecancer (NMIBC). Efter behandling opstarter patienterne kontrolforløb med gentagne kikkertundersøgelser af blæren. For nogle er disse kontrolforløb livslange. Den årlige risiko for tilbagefald ved NMIBC er 35 %.

Pga. de gentagne tilbagefald og kontroller er NMIBC en af de dyreste kræftformer fra diagnose til død.

 

I Danmark har de urologiske afdelinger haft forskellige behandlingsstrategier for NMIBC. Der er således forskel på anvendelsen af sporstof (photodynamic diagnosis, PDD) under kikkertoperation og på brugen af kemoterapi til blæreskyllebehandlinger.

 

Formålet med dette PhD-studie er at undersøge, om én behandlingsstrategi for NMIBC er de andre overlegen. Dette både i forhold til antallet af tilbagefald og udvikling i kræftstadiet over tid, men også i forhold til de blæresymptomer og påvirkning af blærefunktionen, som patienterne får pga. behandlingen. Hvis man kan finde en optimal behandlingsstrategi i fht. dette, vil det medføre forbedret patientforløb og dermed øget livskvalitet for denne store patientgruppe fremadrettet.

 

PhD-studiet vil blive udført som dels et registerbaseret nationalt kohorte studie og dels som et deskriptivt studie på en mindre patientgruppe. Patienterne identificeres ud fra nationale databaser, og de danske, urologiske afdelinger klassificeres i forhold til deres behandlingsstrategi ud fra spørgeskemaer. Brugen af blærerelateret medicin anvendes som et surrogat mål for blæresymptomer, mens blærefunktionen bestemmes ved hjælp af en detaljeret blæreundersøgelse (urodynamisk undersøgelse), som udføres af den PhD-studerende på udvalgte patienter.

 

Der er ikke tidligere lavet undersøgelser, som kobler NMIBC-behandling med de følgevirkninger, som patienterne får. Resultaterne af dette PhD-studie forventes derfor at blive essentielle for behandlingsstrategierne for NMIBC fremover.  Således forsøges at opveje fordele og ulemper ved forskellige behandlinger både i forhold til effekt mht tilbagefald, men også mht indflydelse på blærefunktion og dermed livskvalitet.

Contact:

Phd student: Linea Blichert-Refsgaard
Main supervisor: Jørgen Bjerggaard Jensen

Title: BC-DEEDS Study – Bladder Cancer Deep Learning Diagnostics Study. – Can a deep learning tool improve diagnostics in patients with bladder cancer?

Aim: As bladder cancer has a high recurrence and progression rate knowledge of tumor grade is essential to perform an optimal resection. However, visual estimation by the surgeon regarding tumor grade is poorly correlated to the true histopathological tumor grade, which is the main reason for the high recurrence rate and delay of relevant adjuvant treatment.

The project aim at training a Convolutional Neural Network (CNN) to improve detection of bladder lesions and assist in the prediction of the histopathological diagnose.

By using a CNN-model to classify bladder lesions and predicting tumor grade the vision for the project is to improve the overall management of patients with NMIBC.

Number of patients: 3200 patients

Methods: A prospective study where video data and images from flexible cystoscopy or TUR-B will be used to produce a trained CNN-model, which can be implemented in a software-application to detect various bladder lesions. Data on non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC), Carcinoma In Situ (CIS), inflammation, cystitis cystica and normal bladder mucosa is included in the data set.

Participants for this study are patients eligible for cystoscopy or TUR-B. There will be no changes in regular procedure for these patients, nor in the follow up of their disease.

Status: ongoing

Sites: Department of Urology at Aarhus University Hospital and Regional Hospital of Holstebro

Contacts:

Jacob Elmose Jensen, MD. E-mail: jabjns@rm.dk

Anna Munk Nielsen, Clinical Trial Coordinator. E-mail: annanils@rm.dk

Treatment

Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC – NICSA

Aims:

To assess the efficacy and tolerability of dose dense chemoresection with mitomycin C compared to standard treatment with TURBT and adjuvant instillations

To asses predictive tumour biomarkers to chemoresection with mitomycin C

Number of patients: 120

Methods: The study is a randomised controlled trial with two treatment arms. Included patients had a history of low-grade or high-grade Ta bladder tumours and were included upon recurrence with multiple tumours smaller than 2 cm. The intervention group underwent short-term intensive chemoresection with mitomycin C thrice a week for two weeks. Tumour response was evaluated by flexible cystoscopy four weeks after treatment completion. The control group underwent TURBT or outpatient biopsy and tumour fulguration followed by six weekly adjuvant intravesical instillations: mitomycin C for low-grade tumours and BCG for high-grade tumours.

Status: Patient inclusion was completed in June 2019. The first results are published and available at: https://doi.org/10.1016/j.eururo.2020.07.009

Sites:

– Department of Urology, Aarhus University Hospital, Aarhus, Denmark

– Department of Urology, Gødstrup Hospital, Gødstrup, Denmark  

Contacts: PhD student Maria Skydt Lindgren, email: maalin@rm.dk

ClinicalTrials.gov: NCT03348969

Titel: Optimal approach for T1 bladder cancer – Clinical relevance of subclassification in T1 bladder cancer

Background: Bladder Cancer (BC) is the 10th most commonly diagnosed cancer worldwide. Approx. 450 patients are diagnosed with tumour stage T1 BC in Denmark (DK) each year. In DK, the 5-year overall- and cancer specific survival (CSS) after the diagnosis of T1 BC is approx. 60% and 80%, respectively.

In most industrialized countries, T1 BC is treated with tumour resection and BCG bladder instillation. However, the 5- and 10-year risk of progression to muscle invasive BC (MIBC) with this approach is 31% and 42% respectively. In addition, patients that progress from T1 BC to MIBC have a 5-year CSS of < 50% compared 67% for patients with primary MIBC.

In DK T1 BC is sub classified into T1a and T1b. Most T1a patients will receive tumour resection and BCG instillation and most T1b patients will receive surgical removal of the urinary bladder.

No studies have compared the Danish approach with the more conservative and widespread bladder preserving approach.

Aim:

Study 1: To investigate the prognostic value of T1 BC sub classification.

Study 2: To compare the prognosis of T1 BC patients diagnosed in DK and Sweden.

Study 3: To investigate the reproducibility and the clinical relevance of a new pathological definition of the T1 BC sub classification.

Methods:

Study 1: Danish national data on T1 BC patients diagnosed from Sept. 2012 to Aug. 2018 will be retrieved. Data on T1a and T1b patients will be compared.

Study 2: For the same period as in study 1, data on T1 BC patients from DK will be compared with data on T1 BC patients for Sweden.

Study 3: For the same period as in study 1, pathological tissues from Danish T1 BC patients will get re-evaluated according to a new definition.

Statistical analysis: In all three studies overall-, cancer specific-, recurrence free- and progression free survival will be compared using cox proportional hazard regression analysis stratified on treatment modality and adjusted for gender, age and comorbidity. For study 3, interrater agreement will be calculated using Cohen´s Kappa.

Perspective: The study will evaluate whether T1 subclass. in T1a and T1b should be recommended on an international level with potential positive effect on oncological outcomes. In addition, the results from this study are expected to contribute with updated knowledge on the treatment of T1 BC. Hereby to provide cancer urologists with updated knowledge to allow optimal guidance of T1 BC patients regarding treatment of their BC disease.

Contact:

Phd student: Erik Hansen
Main supervisor: Jørgen Bjerggaard Jensen

En bloc transurethral resection of non-muscle invasive bladder cancer

Bladder cancer is the tenth most common cancer in the world, and approximately 75% present with non-muscle invasive bladder cancer (NMIBC). The cornerstone in diagnosis and removal of bladder tumours is transurethral resection (TURB) where the tumour is dissected in pieces, removed from the bladder, and then pathologically examined to identify potential detrusor muscle invasion. This method leads to two problems: first, incomplete resection of tumour and possible scattering of tumour cells may lead to recurrence. Second, pathological examination is impaired since tumour margins cannot be properly assessed. Thus, infiltration of suburothelial tissue or detrusor muscle may be underestimated or even missed.

En bloc resection (EBR), where the tumour is removed in total, is supposed to overcome the above mentioned flaws of conventional TURB.

We will conduct a randomised controlled multicentre trial comparing EBR to conventional TURB in patients with non-muscle invasive bladder cancer. We hypothesize EBR to be a superior operation technique to conventional TURB regarding both short-term outcomes, such as pathological assessment quality, as well as long-term outcomes. Primary endpoint will be recurrence free survival.

This study will provide insight whether EBR can improve surgical quality and reduce recurrence rates and thereby costs for patients and society.

Contact:

Phd student: Ninna Kjær Nielsen
Main supervisor: Jørgen Bjerggaard Jensen

Aim: to evaluate whether EpiCheck can be used as a predictor of tumour response to short-term intensive chemoresection with mitomycin C

Number of patients: 22

Methods: the Bladder Epicheck® test is a diagnostic device for the detection of urinary DNA methylation-patterns associated with bladder cancer. DNA methylation is an epigenetic modification often involved in bladder cancer. The EpiCheck test is based on analysis of 15 DNA methylation biomarkers, of which the EpiCheck software calculates a methylation score. The score ranges from 0-100 representing the overall methylation level from low to high. A score above 60 is considered positive and corresponding to a high risk of recurrent bladder cancer.

The study is a prospective observational study without randomisation. Eligible patients; have a history of Ta high-grade bladder tumours, are diagnosed with a recurrence and referred to short-term intensive chemoresection with mitomycin C. The treatment adhere to the regimen described in the NICSA and DaBlaCa-13 trial. Treatment consists of short-term, intensive chemoresection with mitomycin C thrice weekly for two weeks. To evaluate tumour response, an early cystoscopy is performed in the outpatient clinic four weeks after treatment completion. Subsequently patients continue a standardised follow-up program assuming Danish guidelines, which is initiated after fourth months. The EpiCheck test is performed at baseline and if the result is positive, the test is repeated prior to the fourth and sixth instillation with mitomycin C as well as prior to the subsequent two cystoscopies. Urine cytology is performed simultaneously with the EpiCheck test. Clinicians are blinded to the EpiCheck result.

Status: Patient inclusion is ongoing with four patients included.

Sites:

  • Department of Urology, Aarhus University Hospital, Aarhus, Denmark
  • Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
  •  

Contacts:

Ph.d. student Maria Skydt Lindgren, email: maalin@rm.dk

Ph.d. student Thomas Karmark Dreyer, email: thromas.dreyer@rm.dk

ClinicalTrials.gov: NCT04162704

 

Title: North-Reg Dwell Time Study

Aim: The aim of this study is to investigate whether reduced dwell time (DT), being the time the bladder is exposed to Bacillus Calmette Guérin (BCG), will decrease the severity of side effects due to BCG instillations compared to the current DT at 2 hours.

Previous studies show that approximately 70% of non-muscle invasive bladder cancer patients experience side effects when treated with BCG. When installed in the bladder BCG causes an immune response killing the bladder cancer cells. Because of the side effects, patients terminate their instillations before completing all planned instillations, resulting in an increased risk of recurrence and progression.

Number of patients: 314

Methods: The trial is designed as a multi-center, multi-national, two-armed, randomized, open-label, investigator-initiated clinical controlled – phase IV trial.

To monitor the patients side effects they will receive daily questionnaires in the instillation weeks. The side effects will be categorized according to a predefined algorithm and if patients in the intervention arm experience side effects of a certain severity, they will be reduced in DT. 

Status: recruiting in Aarhus and Holstebro

Sites:
1. Department of Urology, Aarhus University Hospital, Denmark
2. Department of Urology, Herlev University Hospital, Denmark
3. Department of Urology, Roskilde Regional Hospital, Denmark
4. Department of Urology, Aalborg University Hospital, Denmark
5. Department of Urology, Holstebro Regional Hospital, Denmark
6. Department of Urology, Rigshospitalet, Copenhagen University Hospital, Denmark
7. Department of Urology, Odense University Hospital, Denmark
8. Department of Urology, Örebro Regional Hospital, Sweden
9. Department of Urology, PO Salgrenska University Hospital, Sweden
10. Department of Urology, Landspitalinn University Hospital, Iceland
11. Department of Urology, Vestfold Hospital, Norway
12. Department of Urology, Karolinska University Hospital, Sweden

Contacts: PhD student, MD, Lene Munk, Mail: lenemu@rm.dk

Clinicaltrial.gov: 04701151 

Title: Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy – The URODYN trial

Aim: to evaluate the impact of different treatment strategies in non-muscle invasive bladder cancer on bladder function

Number of patients: 50

Methods: the study is conducted as a prospective observational study without randomisation. Eligible patients are diagnosed with primary non-muscle invasive bladder cancer or with their first or second recurrence and will be enrolled at the time of TURBT. Four to six weeks later, all patients will have an urodynamic examination performed, which will be repeated after six months. In total, 50 patients are to be included; 30 patients will have no further treatment, and 20 patients will have six adjuvant intravesical instillations administered between the first and second urodynamic examination. Mitomycin C will be administered in 10 patients with low-grade disease, while bacillus Calmette-Guérin will be administered in 10 patients with carcinoma in situ, T1 tumour stage or high-grade disease. In parallel, patients follow a standardised follow-up program assuming Danish guidelines, which is initiated fourth months after TURBT.

Status: Patient inclusion is ongoing

Site: Department of Urology, Aarhus University Hospital, Aarhus, Denmark

Contact: Ph.d. student Linea Blichert-Refsgaard, email: lineblic@rm.dk

ClinicalTrials.gov: NCT04943094.

Follow-up

Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor – SEALS Xpert

Title: Surveillance of high grade non-muscle invasive bladder tumours using the Xpert Bladder Cancer Monitor – SEALS

Aim: To investigate the feasibility of the Xpert Bladder Cancer Monitor as a substitute for cystoscopy in the follow-up of non-muscle invasive bladder cancer.

Number of patients: 392 patients needed for 2 arms.

Methods:
Multicenter, non-inferiority randomized clinical trial

Status: ongoing

Sites: Regional Hospital West Jutland, Zeeland University Hospital at Roskilde, Aalborg University Hospital and Aarhus University Hospital

Contacts:
Primary investigator: MD, Ph.d.-student Thomas Karmark Dreyer thomas.dreyer@rm.dk

Clinicaltrial.gov: NCT04100733 

Title: Surveillance of low-grade non-muscle invasive bladder tumours using Uromonitor – SOLUSION Uromonitor

Aim: The study aim at evaluating the potential clinical impact of the Uromonitor-test regarding possible reduction in number of cystoscopies, without increasing the risk of progression. 

Number of patients: 160 subjects

Methods:
‘Uromonitor’ is an non-invasive urine based IVD diagnostic test.

The study is designed as a multicenter observational clinical trial. Patients scheduled for follow-up cystoscopy due to previous low grade NMIBC disease within the first 2 years from diagnosis, where no recurrence is found at cystoscopy, will be offered inclusion in the study.

Cystoscopy and Uromonitor test is performed at the time of inclusion. Patients with negative Uromonitor test and no visualization of tumor will be scheduled for a Uromonitor test every 4 months and Uromonitor test and cystoscopy after 8 and 24 months from the time of diagnosis for newly diagnosied patientes and after 12 and 24 months from the time of inclusion for perviousely diagnosied patients. Patients with positive Uromonitor test and no visualization of tumor at cystoscopy will be scheduled for cystoscopy as standard follow up without additional intervention. Recurrent tumors detected by cystoscopy will be handled according to current Danish guidelines.

Status: Recruiting at all sites

Sites in Denmark:

Department of Urology, Zealand University Hospital, Roskilde

Department of Urology, Aarhus University Hospital

Contacts:

Thomas Karmark Dreyer, MD Sub-PI. thmacris@rm.dk

Professor Jørgen Bjerggaard Jensen. Bjerggaard@skejby.rm.dk

muscle-invasive bladder cancer

Etiology

Titel: Influence of Hormone Treatment in Bladder Cancer – incidence, prognosis and functional outcome

Aim: To investigate the role of sex hormone receptors in the bladder and their potential role in the gender difference seen in the disease. Furthermore, this study aims to investigate if anti-hormonal treatment targeting these receptors is useful in the treatment for bladder cancer.

Number of patients: 100.000

Methods: Register-based follow up cohort study. Patients are included from Danish National Registries. Patients diagnosed with prostate cancer, breast cancer or endometrial are included as cases and matched with a control group without cancer. Primary endpoint is bladder cancer diagnosis. Furthermore, patients are divided into sub-groups depending on the type of anti-hormonal treatment they receive.

Status: Ongoing

Sites: Department of Urology, Aarhus University Hospital

Contacts: PhD Student Josephine Hyldgaard, email: josehyld@rm.dk

Diagnosis

Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MR – MAINTAIN

For patients with MIBC treated with NAC and radical cystectomy there is currently no good way of evaluating whether the patient is true T0 or has remnant tumor in need for consolidating radical treatment. Methods for better selection of patients that potentially can avoid cystectomy is therefore needed.

15O-labeled water (H2O) is the gold standard for PET quantification of regional tissue perfusion. 15O-H2O has been validated as a freely diffusible tracer for measuring perfusion in the myocardium and cerebral blood flow and 15O-H2O PET is the golden standard for noninvasive imaging to quantify tumor blood flow (TBF).

Method: Patients scheduled for NAC followed by radical cystectomy due to histologically documented MIBC stage cT2-4a in the urinary bladder will be included. A 15O-H2O PET/MR scan will be performed at time of inclusion (baseline) and again after NAC prior to cystectomy.

Hypothesis: We hypothesize that changes in tumor architecture and perfusion estimated with 15O-H2O PET/MR measurements and clinical evaluation during NAC can identify patients with complete local response to chemotherapy and therefore select patients to avoid radical cystectomy.

Perspectives: This study will be the first to use 15O-H2O as tracer in bladder cancer. If proven efficient, evaluation of patients undergoing NAC with 15O-H2O PET/MR could potentially safely select patients for a true bladder sparring approach and potentially give some patients the choice of chemotherapy monotherapy, or in combination with other systemic oncological treatments like immunotherapy. If successful, this should be followed by randomized studies to document the clinical benefit and potentially reduce cost and increase quality of life by safely selecting patients for bladder sparring treatment of bladder cancer.

Contact:

Phd student: Stefanie Korsgaard Körner
Main supervisor: Jørgen Bjerggaard Jensen

Treatment

Title: Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer – DaBlaCa 18

Aim: To determine if concomitant treatment with androgen deprivation therapy during radiation therapy (RT) for bladder cancer is associated with a lower risk of radiation side effects such as fibrosis, decreased bladder compliance and overall decreased quality of life.

Number of patients: 63

Methods: Prospective, observational cohort study. Patients are included when diagnosed with muscle invasive bladder cancer and are scheduled to receive radiation therapy with or without concomitant treatment with androgen deprivation therapy. Before and during the RT patients will receive questionnaires regarding side effects. After completion of the RT, they will undergo a cystoscopy with biopsy in which degree of fibrosis will be determined. Finally, they will complete questionnaires and urodynamic examination 3 months after completing RT and again 12 months later.   

Status: Ongoing

Sites:

  • Department of Urology, Aarhus University Hospital
  • Department of Urology, Odense University Hospital
  •  

Contacts: PhD Student Josephine Hyldgaard, email: josehyld@rm.dk

Clinicaltrial.gov: NCT04282876 

Titel: MOSAIC – Modified Urinary Conduit to Lower Strictures After Radical Cystetomy – DaBlaCa – 16

Aim: To compare the rate of left sided ureteral strictures after radical cystectomy between the modified retrosigmoid conduit (Interventions Group) and the standard urinary conduit (Control group). 

Number of patients: 300

Methods: This project is a randomized controlled trial where patients undergoing cystectomy are randomized between the modified conduit and the conventional ileal conduit ‘ad modum Bricker‘.  Primary endpoint is the rate of ureterenteric strictures, and secondary endpoint is both surgical complications and renal function within 24 months.

Status: Ongoing

Sites:

Department of Urology, Aalborg University Hospital

Department of Urology, Aarhus University Hospital

Department of Urology, Odense University Hospital

Department of Urology, Rigshospitalet

Department of Urology, Herlev and Gentofte Hospital

Contact:

Phd student: Simone Buchardt Brandt, email: simbra@rm.dk

Clinicaltrial.gov: NCT04391790

Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy – EGIAES

Cystectomy with urinary diversion is the standard treatment of muscle invasive and high risk non-muscle invasive bladder cancer. During cystectomy, a urinary diversion is constructed from a bowel segment. Restoration of the intestinal continuity is therefore an obligate part of the procedure.

In Denmark, approximately 400 radical cystectomies are performed yearly with the majority of procedures performed as a laparoscopic robot assisted procedure. This includes urinary diversion by means of intracorporeal procedure.

During current standard intracorporeal urinary diversion, an Endo-GIA stapler is handled by the assisting surgeon and not by the main surgeon as the Endo-GIA stapler is not integrated into the robot.

The traditional Endo-GIA anastomosis is made as a side-by-side anastomosis with two 60 mm magazines: one for the side-to-side anastomosis and one for closing the end.

Any reduction in the lumen of the anastomosis will clinically affect post-operative bowel function. It is known that at all cystectomy patients have intestinal paralysis / lack of normal bowel function in the first days postoperatively. It is thus plausible that a wider anastomosis will be able to reduce the duration of this in favor of the patient’s post-operative nutrition, postoperative length of stay and convalescence.

A stapler integrated in the robot (Endowrist stapler from Intuitive) is available. This has several advantages: it is operated by the robotic surgeon and not by the assistant, it is more flexible, and faster mobility. These advantages provide the possibility of precisely removing a minimal intestinal segment by the final transverse stapling. The biggest disadvantage of the robot-operated Endowrist staple is that it is not available in a 60 mm version but only in 45 mm, thus giving only an anastomosis of approximately the same lumen as using a 60 mm Endo-GIA staple but not better.

An opportunity to make a more spacious anastomosis would be to “prolong” the longitudinal stapling as to the side-to-side anastomosis between the intestinal segments. This requires precise and coordinated handling of bowel graspers and staplers to make a complete elimination of the risk of anastomosis leakage, which in this respect is an advantage of robot-operated staples with the Endowrist stapler rather than an assistant handled stapler with Endo-GIA.

Both Endo-GIA and Endowrist stapler are approved for clinical use according to the procedures described.

 

Contact: 

Professor Jørgen Bjerggaard Jensen

Follow-up

Titel: TOMBOLA – Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy – DaBlaCa 14

Aim: The study aim at investigate the response rate and oncological outcome of early systemic immunotherapy treatment with the PDL-1 inhibitor Atezolizumab. The study drug is administered at the time of biochemical relapse e.g. circulating tumor DNA (ctDNA positive) in patients who have undergone radical cystectomy due to muscle invasive bladder cancer. Biomarkers that predict response to systemic immunotherapy will be identified by comprehensive multi-omics analysis of primary tumors and metastatic lesions. Furthermore, the trial aim to determine if ctDNA levels during therapy can be used as a biomarker for early indication of therapy response.

Number of patients: 282 patients

Methods: The study is conducted as a Single Country, Open-label, Single-arm, Non-randomized, Phase II study where intervention is given based on an experimental design.

Sensitive molecular techniques for detection of tumor DNA in the blood is performed to identify patients with early metastatic disease.

The study drug will be administered according to current recommendations as systemic treatment every third week for a maximum of 12 months or until progression. Treatment will be initiated within 28 days of diagnosis of ctDNA relapse.

Status: Open for inclusion at both main- and sub sites.

Sites:

Dept. Of Urology and Oncology from:

  • Aarhus University Hospital
  • Herlev Hospital
  • Rigshospitalet
  • Odense University Hospital
  • Aalborg University Hospital

Contacts:

National Trial Coordinator: Anna Munk Nielsen. E-mail: annanils@rm.dk

Sponsor-Investigator: Jørgen Bjerggaard Jensen. E-mail: bjerggaard@skejby.rm.dk

Clinicaltrial.gov: NCT04138628

Titel: Nordic cystectomy biomarker validation study – NorCys

Muscle-invasive bladder cancer (BC) is an aggressive malignancy and radical cystectomy (RC) with pelvic lymph node dissection (PLND) is the gold standard of therapy. In addition to surgery, neoadjuvant chemotherapy (NAC) is recommended for patients who are fit for cisplatin-based chemotherapy based on results from prospective trials. In the Nordic countries approximately 7.200 new BC cases are diagnosed annually and mortality is 2.100 cases per year. We estimate that about 1.200 RCs are performed due to MIBC in Nordic countries per year.

Currently the tools for estimating prognosis and risks are insufficient and improved ones are needed.

Aims:

The rationale for the study is to gather, in a prospective, multi-institutional and international design, data of patients undergoing RC for MIBC in Nordic countries. The collected data will be used with the aim of validating existing prediction tools and discover novel tools for

1) prediction of morbidity related to RC.

2) prediction of oncological outcome after RC.

3) prediction of response to NAC prior to RC.

The hypothesis is that with this study we can meet the abovementioned aims and develop a well-documented model for prediction of individual patient outcome regarding RC. 

Sites: This study is in collaboration with all the Nordic countries, through the Nordic Urothelial Cancer Research Group, led by Peter Boström, Cheif at the Department of Urology at Turku University Hospital, Finland.

Read more: http://north-reg.nu/

Contact:

PhD student Simone Buchardt Brandt, email: simbra@rm.dk

Professor Jørgen Bjerggaard Jensen 

Clinicaltrial.gov: NCT04523025, NCT04537221, NCT04523038

Title: Surveillance of low-grade non-muscle invasive bladder tumours using Uromonitor

Aim: The’ study aim at evaluating the potential clinical impact of the ‘Uromonitor-test’ in the surveillance program of Low Grade NMIBC. The study will evaluate if the non-invasive surveillance test can reduce the number of flexible cystoscopies, without increasing the risk of progression.

Number of patients: 160 subjects

Methods:

The study is designed as a multicenter observational clinical trial. Patients scheduled for follow-up cystoscopy due to previous Low Grade NMIBC within the first 2 years from diagnosis, where no recurrence is found at the current cystoscopy, will be offered inclusion in the study.

At each visit (baseline, 4, 8, 12, 16, 20 and 24 months from inclusion) the study subjects will contribute with a urine sample of 20 ml. The specimen will analysed according to protocol using the ‘Uromonitor’ test.

Status: Open for inclusion

Sites:

Sponsor-site: Department of Urology, Zealand University Hospital, Roskilde. 

Sub-site: Bladder Cancer Research team, Dept.of Urology

Contacts:

Sub-Investigator: Thomas Karmark Dreyer, MD, thomas.dreyer@rm.dk

Principal Investigator: Jørgen Bjerggard Jensen, MD, DMSc, Bjerggaard@skejby.rm.dk

Sponsor- investigator: Nessn H. e. Azawi, MD. Ph.D. nesa@regionsjaelland.dk

Clinicaltrial.gov: NCT03962933    

Biorepository

Title: Bio – and Genome Bank Denmark

Aim: The biorepository aims specifically at creating a solid foundation for research in bladder cancer to develop new methods for optimal diagnose and personalized treatment.

Number of patients: >5600 participating patients from the Central Denmark Region

Methods: Denmark has a long tradition of collection biological specimen from various disease categories. In patients diagnosed with bladder cancer the biological specimen has been collected prospectively since 1994. The bladder cancer biorepository represents samples from disease categories as Carcinoma In Situ, pTa LG and HG, pT1-4. The collection of blood, urine and tissue from patient with NMIBC and MIBC has been ongoing since 1994. Patients are included in the biobank at the time of diagnosis, and samples are collected at each hospital visit throughout the course of treatment and follow-up visits. When processed the material is shipped to Department of Molecular Medicine at Aarhus University Hospital. The large cohort represents a unique and valuable material for researchers and clinicians in their investigation of expected disease progression, probability of recurrence, response to treatment ect. The repository contains detail information on clinical characteristics, types of treatment, pathological reports ect.

Sampling events for patients included in the bladder cancer biorepository at Aarhus University Hospital:

Samples per visit:

Liquid biopsies: 2x 10 mL. lavender top EDTA, 2x 10 mL serum separation tube, 2 x 4,5 mL urine and 1x tumor tissue biopsy.

Status:

  • 1-5 tumor tissue samples from each patient
  • > 13000 vials with full blood
  • > 3300 vials buffy coat
  • > 36000 urine samples


Sites: Aarhus University Hospital and Regional Hospital West Jutland

Contacts:

Medical laboratory technologists

Jameela Safi: jamesafi@rm.dk

Birgitte Nielsen: Birgitte.Nielsen@aarhus.rm.dk

Klinisk relevante biomarkører til forudsigelse af sygdomsforløb og terapirespons hos patienter med blærekræft er stadig ikke blevet identificeret trods en intensiv forskningsindsats. Nye teknologiske fremskridt indenfor kortlægningen af vores arvemasse (genom) har gjort det muligt at identificere genomiske ændringer, som er specifikke for den enkelte patients tumor. Det er derfor nu muligt at bruge disse teknologiske fremskridt til bedre kontrol af den enkelte patients sygdom.

Dette projekts formål er vha. ”Next Generation Sequencing” (NGS) at identificere mutationer og genomiske ændringer i genomet i tumorer fra patienter med blærekræft. Ændringerne vil blive anvendt som patient-specifikke markører til at følge sygdomsudviklingen over tid. De specifikke formål med projektet er:

Identifikation af specifikke markører til test af urinprøver hos patienter med ikke muskelinvasiv blæretumor som følges med cystoskopiundersøgelser

Identifikation af specifikke markører til test af blodprøver hos patienter med muskelinvasiv blærekræft behandlet med neoadjuvant kemoterapi og efterfølgende cystektomi

Identifikation af specifikke markører til test af blodprøver hos patienter med avanceret muskelinvasiv blærekræft behandlet med kemoterapi 

Med dette projekt vil vi belyse, om det er muligt at identificere sygdomstilbagefald og sygdomsforværring på et tidligere tidspunkt vha. urin og blodprøver, og dermed forbedre overlevelsen for patienter med blærekræft. Yderligere vil vi undersøge om vi, vha. personlige biomarkører, kan undgå gentagne kikkertundersøgelser af blæren, og dermed spare patienterne for smerter og bivirkninger ved dette, samt spare store udgifter forbundet med de nuværende kontrolundersøgelser. Desuden vil vi med projektet belyse, om vi kan identificere spredning af sygdommen tidligere. Dermed vil man kunne igangsætte kemoterapi på et tidligere tidspunkt, hvilket ultimativt vil kunne forbedre patienternes overlevelse. Endelig vil måling af kemoterapi-effektivitet ultimativt sikre, at patienterne tilbydes den relevante behandling.  

Contact:

Professor Jørgen Bjerggaard Jensen and clinical trial coordinator Anna Munk